Late Breakers
Top 5 Industry Updates
Chronic Hand Eczema Affects Patients’ Emotional, Social, and Occupational Well-Being
U.S. FDA Approves Dupilumab (Dupixent, Sanofi & Regeneron) for CSU, Marking the Seventh Disease State Approval for the IL-4 and IL-13 Blocker
Dupilumab is first targeted therapy to be approved for CSU in a decade.
Industry Information
ICYMI: RINVOQ® Shows Superiority Over DUPIXENT® in Atopic Dermatitis Study
New data reveals that RINVOQ® outperformed DUPIXENT® across all measured endpoints in a head-to-head study on atopic dermatitis, demonstrating promise for clearer skin and reduced itching.
Once-daily Oral Icotrokinra Shows Efficacy in Adolescents With Moderate to Severe PsO
Three-quarters of adolescents with PsO treated with investigational icotrokinra (JNJ-2113) achieved completely clear skin with no new safety signals identified, according to data from a subgroup analysis of ICONIC-LEAD.
Industry Information
What’s New for Otezla: New Indication & New Data
Now approved for pediatric patients aged 6+ years with moderate-to-severe plaque psoriasis and new real-world patient data in plaque psoriasis.
Unraveling the Role of Type 2 Inflammation in AD, PN, and CSU
AD, PN, and CSU are unified by a dysregulated type 2 immune response that involves type 2 cytokines such as IL–4, IL–3, and IL–31 interacting with immune cells, sensory nerves, keratinocytes, fibroblasts, and other cells of the skin.
